Genedrive PLC Director/PDMR Shareholding (0927V)
19 July 2018 - 4:00PM
UK Regulatory
TIDMGDR
RNS Number : 0927V
Genedrive PLC
19 July 2018
Notification and public disclosure of transactions by persons
discharging
managerial responsibilities and persons closely associated with
them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the
near patient molecular diagnostics company, announces that it on 17
July 2018 share options ("Options") were granted to certain of its
directors to acquire a total of 486,306 ordinary shares of 1.5p
each in the capital of the Company under the Company's 2017 Share
Option Scheme.
The Options have been granted with an exercise price equal to
the closing price on the day before grant and vest after a period
of three years if certain performance criteria are met. The Options
are exercisable over the period of 10 years from the date of
grant.
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a. Name 1. David Budd
2. Matthew Fowler
------------------------------ ----------------------------------------------------------
2. Reason for the notification
------------------------------------------------------------------------------------------
a. Position/status 1. CEO
2. CFO
------------------------------ ----------------------------------------------------------
a. Initial notification Initial notification
/Amendment
------------------------------ ----------------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------
a. Name genedrive plc
------------------------------ ----------------------------------------------------------
b. LEI 213800ZYODIRZ87Y4K14
------------------------------ ----------------------------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------------------
a. Description of Options over ordinary shares of 1.5 pence
the each
Financial instrument,
type
of instrument
Identification
code
------------------------------ ----------------------------------------------------------
b. Nature of the Grant of options pursuant to and in accordance
transaction with the terms of the Company's Share Option
Scheme dated 5 December 2017.
------------------------------ ----------------------------------------------------------
c. Price(s) and Price(s) Option Volume(s)
volume(s) price(s)
David Budd 30.5p 222,260
---------- ----------
Matthew Fowler 30.5p 264,046
---------- ----------
------------------------------ ----------------------------------------------------------
d. Aggregated information
* Aggregated volume N/A
* Price
------------------------------ ----------------------------------------------------------
e. Date of the transaction 2018-17-07; UTC time
------------------------------ ----------------------------------------------------------
f. Place of the Outside trading venue - shares to be admitted
transaction to AIM market of London Stock Exchange plc
on exercise of options
------------------------------ ----------------------------------------------------------
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO
Matthew Fowler: CFO
Peel Hunt LLP +44 (0)207 418 8900
James Steel
Oliver Jackson
Stanhope Capital Ltd +44(0)203 815 8880
Patrick Claridge
Consilium Strategic Communications +44 (0)203 709 5700
Chris Gardner
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEANXPFFDPEFF
(END) Dow Jones Newswires
July 19, 2018 02:00 ET (06:00 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024
